Evidence map›Paper›PMID 29775485›Full record

ArticlePLoS pathogens2018

Plasmodium parasite exploits host aquaporin-3 during liver stage malaria infection.

Dora Posfai, Kayla Sylvester, Anupama Reddy, Jack G Ganley, Johannes Wirth, Quinlan E Cullen, Tushar Dave, Nobutaka Kato, Sandeep S Dave, Emily R Derbyshire

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. To quest new targets ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Novel Therapeutics for Malaria.Pharmaceutics · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Host-parasite interactions duringFrontiers in immunology · 2022
    Review
  19. Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.Frontiers in cellular and infection microbiology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dora PosfaiDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, North Carolina, United States of America.ORCID 0000-0003-3965-6456
Kayla SylvesterDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, North Carolina, United States of America.ORCID 0000-0003-4570-7432
Anupama ReddyDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Jack G GanleyDepartment of Chemistry, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0003-3039-7398
Johannes WirthDepartment of Chemistry, Duke University, Durham, North Carolina, United States of America.
Quinlan E CullenDepartment of Chemistry, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0003-0518-2264
Tushar DaveDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-7257-4631
Nobutaka KatoThe Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts, United States of America.
Sandeep S DaveDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Emily R DerbyshireDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, North Carolina, United States of America.ORCID 0000-0001-6664-8844
Duke Medical Center · USDuke University · USBroad Institute · US

Funding

Enabling Host Processes for Defense Against Liver Stage Malaria InfectionDP2AI138239 · NIAID · DUKE UNIVERSITY · PI DERBYSHIRE, EMILY R · 2017 to 2017
$2.3M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
NIAID NIH HHS DP2 AI138239NIH HHS 1DP2AI138239NIH HHS S10 OD018164
6 · The paper itself

Abstract

Within the liver a single Plasmodium parasite transforms into thousands of blood-infective forms to cause malaria. Here, we use RNA-sequencing to identify host genes that are upregulated upon Plasmodium berghei infection of hepatocytes with the hypothesis that host pathways are hijacked to benefit parasite development. We found that expression of aquaporin-3 (AQP3), a water and glycerol channel, is significantly induced in Plasmodium-infected hepatocytes compared to uninfected cells. This aquaglyceroporin localizes to the parasitophorous vacuole membrane, the compartmental interface between the host and pathogen, with a temporal pattern that correlates with the parasite's expansion in the liver. Depletion or elimination of host AQP3 expression significantly reduces P. berghei parasite burden during the liver stage and chemical disruption by a known AQP3 inhibitor, auphen, reduces P. falciparum asexual blood stage and P. berghei liver stage parasite load. Further use of this inhibitor as a chemical probe suggests that AQP3-mediated nutrient transport is an important function for parasite development. This study reveals a previously unknown potential route for host-dependent nutrient acquisition by Plasmodium which was discovered by mapping the transcriptional changes that occur in hepatocytes throughout P. berghei infection. The dataset reported may be leveraged to identify additional host factors that are essential for Plasmodium liver stage infection and highlights Plasmodium's dependence on host factors within hepatocytes.

Indexed as

AnimalsAquaporin 3HepatocytesHep G2 CellsHumansLiverLiver DiseasesMalariaMiceParasitesPlasmodium bergheiProtozoan ProteinsSequence Analysis, RNASporozoitesVacuolesAquaporin 3Protozoan Proteins

Identifiers

PMID29775485
PMCPMC5979039
OpenAlexW2803195495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.